STAT+: Telehealth companies swoop in to offer Wegovy pill
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Katie Palmer writes: As drugmaker Novo Nordisk launched the pill version of its popular obesity medication Wegovy on Monday, it aimed to capture patients […]
STAT+: Pharmalittle: We’re reading about AI-designed drugs, an Arrowhead obesity med, and more
Top of the morning to you, and a fine one it is, despite the gray skies hovering over the Pharmalot campus. We are doing our best to maintain sunny spirits, though, because once again, we recall some helpful wisdom from the Morning Mayor, who taught us that “Every new day should be unwrapped like a […]
OPKO Health Bets on RAYALDEE and Pipeline Progress for 2026 Growth
OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, supported by the potential of RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and strategic partnerships. However, stiff competition and overdependence on RAYALDEE pose concerns. Shares of this Zacks Rank #2 (Buy) company have declined 4.5% over the past six months […]
ADHD drugs work, but not the way experts thought – The Washington Post
ADHD drugs work, but not the way experts thought The Washington Post New study shows stimulants work on brain reward, motivation, and wakefulness. psychologytoday.com ADHD Drugs Work Differently? Infant Screen Time; GLP-1 Psychological Side Effects MedPage Today ADHD stimulants don’t work the way we thought they did New Atlas How Do These ADHD Medications Work in the Brain? The […]
Zacks Investment Ideas feature highlights Pagaya, Eli Lilly and Weatherford
For Immediate Release Chicago, IL – January 6, 2026 – Today, Zacks Investment Ideas feature highlights Pagaya Technologies Ltd. PGY, Eli Lilly LLY and Weatherford International WFRD. 3 Top-Ranked Stocks to Buy in 2026 As we enter a new year, the opportunity set in the stock market remains compelling. The US economy has proven more […]
The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson
For Immediate Releases Chicago, IL – January 6, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Eli Lilly and Co. LLY, Medtronic plc MDT, […]
Wegovy Weight-Loss Pill Hits US Market — How Much It Costs, Where to Buy It and How Effective It Really Is
Novo Nordisk’s Wegovy, the first oral GLP-1 weight-loss pill, is now in 70,000+ US pharmacies, costing $5 (£4) to $10 (£7) per day.
Daily Wegovy pill brings GLP-1 weight loss treatment to U.S. adults
When I first started following news about GLP‑1 drugs, everything revolved around injections that patients had to store, handle, and learn to use correctly. Now the arrival of a Wegovy pill in U.S. pharmacies feels like a line in the sand between the first and second era of prescription weight‑loss drugs. As reported by Pharmacy […]
STAT+: Arrowhead’s gene-silencing drugs cut fat in early obesity studies
Arrowhead Pharmaceuticals said Tuesday that its gene-silencing candidates helped people with obesity lose fat, very early results that could intensify the competition among biotechs to develop longer-lasting weight loss drugs. In an ongoing Phase 1/2 study, a cohort of patients took two doses of a candidate called ARO-INHBE, spaced one month apart, in combination with […]
A Systematic Review Identifying Critical Evidence Gaps in Reporting Dietary Change in Randomized Controlled Trials Prescribing Liraglutide, Semaglutide, or Tirzepatide
ABSTRACT Introduction With the growing use of GLP-1/GIP receptor agonist medications, their impact on dietary intake and quality remains unclear. This systematic review examined how randomized controlled trials (RCT) prescribing liraglutide, semaglutide, or tirzepatide assessed and reported dietary intake and quality as outcome measures, alongside weight loss and/or glycemic control, and identified gaps in the […]